These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1890306)

  • 21. Demonstration of the interaction of native C1 with monomeric immunoglobulins and C1 inhibitor.
    Ziccardi RJ
    J Immunol; 1985 Apr; 134(4):2559-63. PubMed ID: 3973388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unusual complement-mediated hemolytic kinetics at low ionic strength.
    Chang NS; Boackle RJ
    Mol Immunol; 1985 Oct; 22(10):1217-24. PubMed ID: 4079941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB; Sjöholm AG
    Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of complement activation and effects of C1-inhibitor on the meconium-induced inflammatory reaction in human cord blood.
    Salvesen B; Nielsen EW; Harboe M; Saugstad OD; Mollnes TE
    Mol Immunol; 2009 Feb; 46(4):688-94. PubMed ID: 18950866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction.
    Thielmann M; Marggraf G; Neuhäuser M; Forkel J; Herold U; Kamler M; Massoudy P; Jakob H
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):285-93. PubMed ID: 16829095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo.
    Hack CE; Hannema AJ; Eerenberg-Belmer AJ; Out TA; Aalberse RC
    J Immunol; 1981 Oct; 127(4):1450-3. PubMed ID: 6168693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C1 dissociation. Spontaneous generation in human serum of a trimer complex containing C1 inactivator, activated C1r, and zymogen C1s.
    Laurell AB; Mårtensson U; Sjöholm AG
    J Immunol; 1987 Dec; 139(12):4145-51. PubMed ID: 2826582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simple one-step hemolytic assay of the first component of human complement (C1) with polyethylene glycol treated human serum: details of the assay procedures and its application to the C1 activation study.
    Nagaki K; Tsuboi M; Matsumoto M; Kitamura H
    J Clin Lab Immunol; 1986 Nov; 21(3):141-6. PubMed ID: 3560192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and regulation of C1 inhibitor in human skin fibroblasts.
    Katz Y; Strunk RC
    J Immunol; 1989 Mar; 142(6):2041-5. PubMed ID: 2537870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The catabolism of C1(-)-inhibitor and the pathogenesis of hereditary angio-edema.
    Lachmann PJ; Rosen FS
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():35-9. PubMed ID: 6587741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma.
    Wuillemin WA; te Velthuis H; Lubbers YT; de Ruig CP; Eldering E; Hack CE
    J Immunol; 1997 Aug; 159(4):1953-60. PubMed ID: 9257861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
    Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
    J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure and function of C1 inhibitor.
    Davis AE
    Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Stepwise dissociation of subcomponents of C1, the first component of human complement, upon activation on an affinity sorbent].
    Kozlov LV; Shoĭbonov BB; Ivanov AE; Zubov VP; Antonov VK
    Biokhimiia; 1989 Oct; 54(10):1745-51. PubMed ID: 2605275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
    Eldering E; Huijbregts CC; Nuijens JH; Verhoeven AJ; Hack CE
    J Clin Invest; 1993 Mar; 91(3):1035-43. PubMed ID: 8450033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-independent activation of C1, the first component of complement, by cardiolipin.
    Kovacsovics T; Tschopp J; Kress A; Isliker H
    J Immunol; 1985 Oct; 135(4):2695-700. PubMed ID: 4031497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the interaction between human plasma kallikrein and C1-esterase inhibitor.
    Nilsson T
    Thromb Haemost; 1983 Jun; 49(3):193-5. PubMed ID: 6554023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of C1-inhibitor function by binding to type IV collagen and heparin.
    Patston PA; Schapira M
    Biochem Biophys Res Commun; 1997 Jan; 230(3):597-601. PubMed ID: 9015369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of human C1r: Western blot analysis reveals slow and dose-dependent activation.
    Hosoi S; Borsos T
    J Immunol; 1988 Sep; 141(5):1610-4. PubMed ID: 2842400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin binding and augmentation of C1 inhibitor activity.
    Caldwell EE; Andreasen AM; Blietz MA; Serrahn JN; VanderNoot V; Park Y; Yu G; Linhardt RJ; Weiler JM
    Arch Biochem Biophys; 1999 Jan; 361(2):215-22. PubMed ID: 9882449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.